^
    Back
    Association details:
    Biomarker:CD73 expression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

    Excerpt:
    Patients (238 total) with first-line metastatic colorectal cancer (mCRC) were randomized to FOLFOX or FOLFIRI chemotherapy ± cetuximab...HER3 and CD73 expression levels were identified as potential predictive markers of benefit from cetuximab.
    Secondary therapy:
    FOLFIRI; FOLFOX
    DOI:
    10.1158/1078-0432.CCR-14-2313